Hattori N, Kurahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M, Saiki Y, Imura H
Department of Endocrinology, Kobe City General Hospital, Japan.
Metabolism. 1992 Apr;41(4):377-81. doi: 10.1016/0026-0495(92)90071-h.
We determined serum growth hormone-binding protein (GHBP), insulin-like growth factor-I (IGF-I), and growth hormone (GH) levels in patients with cirrhosis and in age-matched control subjects, and investigated their relationships. Serum GHBP levels in cirrhotic patients (14.6% +/- 3.9%) (means +/- SD) were significantly lower than those in normal subjects (20.4% +/- 4.7%). GHBP levels had positive correlations with cholinesterase (r = .58, P less than .001) and Normotest (r = .66, P less than .001), both of which represent liver function in cirrhotic patients. Basal GH levels in cirrhotic patients (range, 0.35 to 13.0 micrograms/L; median, 3.9 micrograms/L) were significantly higher than those in normal subjects (0.015 to 6.0 micrograms/L; 0.19 microgram/L). GHBP levels in cirrhotic patients correlated positively with IGF-I levels (r = .39, P less than .01), and negatively with GH levels (r = -.33, P less than .01). These results may indicate that the serum GHBP level reflects the number of hepatic GH receptors, and that the high basal GH level observed in cirrhotic patients is, at least in part, attributable to decreased clearance of GH by these receptors.
我们测定了肝硬化患者及年龄匹配的对照者血清生长激素结合蛋白(GHBP)、胰岛素样生长因子 -I(IGF-I)和生长激素(GH)水平,并研究了它们之间的关系。肝硬化患者的血清GHBP水平(14.6%±3.9%)(均值±标准差)显著低于正常受试者(20.4%±4.7%)。GHBP水平与胆碱酯酶(r = 0.58,P < 0.001)和诺莫测试(r = 0.66,P < 0.001)均呈正相关,这两者均代表肝硬化患者的肝功能。肝硬化患者的基础GH水平(范围,0.35至13.0微克/升;中位数,3.9微克/升)显著高于正常受试者(0.015至6.0微克/升;0.19微克/升)。肝硬化患者的GHBP水平与IGF-I水平呈正相关(r = 0.39,P < 0.01),与GH水平呈负相关(r = -0.33,P < 0.01)。这些结果可能表明血清GHBP水平反映了肝脏GH受体的数量,并且肝硬化患者中观察到的高基础GH水平至少部分归因于这些受体对GH清除率的降低。